ES2526912T3 - Composición farmacéutica que contiene neurotoxina botulínica A2 - Google Patents

Composición farmacéutica que contiene neurotoxina botulínica A2 Download PDF

Info

Publication number
ES2526912T3
ES2526912T3 ES05767871.6T ES05767871T ES2526912T3 ES 2526912 T3 ES2526912 T3 ES 2526912T3 ES 05767871 T ES05767871 T ES 05767871T ES 2526912 T3 ES2526912 T3 ES 2526912T3
Authority
ES
Spain
Prior art keywords
pharmaceutical composition
composition containing
botulinum neurotoxin
containing botulinum
botulinum toxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES05767871.6T
Other languages
English (en)
Inventor
Naveed Panjwani
Paul Webb
Andy Pickett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Biopharm Ltd
Original Assignee
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35063257&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2526912(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0417367A external-priority patent/GB2416692A/en
Priority claimed from GB0421288A external-priority patent/GB2418358A/en
Priority claimed from GB0421290A external-priority patent/GB2418359A/en
Priority claimed from GB0423953A external-priority patent/GB2419527A/en
Priority claimed from GB0423952A external-priority patent/GB2419526A/en
Application filed by Ipsen Biopharm Ltd filed Critical Ipsen Biopharm Ltd
Application granted granted Critical
Publication of ES2526912T3 publication Critical patent/ES2526912T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Birds (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)

Abstract

Toxina botulínica tipo A2 para uso terapéutico, con la condición de que dicha toxina botulínica A2 no se utilice para tratar el hirsutismo o hipertricosis.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14

Claims (1)

  1. imagen1
    imagen2
ES05767871.6T 2004-08-04 2005-08-03 Composición farmacéutica que contiene neurotoxina botulínica A2 Active ES2526912T3 (es)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GB0417367 2004-08-04
GB0417367A GB2416692A (en) 2004-08-04 2004-08-04 Pharmaceutical composition containing botulinum neurotoxin
GB0421288 2004-09-24
GB0421290 2004-09-24
GB0421288A GB2418358A (en) 2004-09-24 2004-09-24 Pharmaceutical composition comprising botulinum neurotoxin
GB0421290A GB2418359A (en) 2004-09-24 2004-09-24 Pharmaceutical composition comprising botulinum neurotoxin
GB0423952 2004-10-28
GB0423953 2004-10-28
GB0423953A GB2419527A (en) 2004-10-28 2004-10-28 Pharmaceutical composition containing botulinum neurotoxin
GB0423952A GB2419526A (en) 2004-10-28 2004-10-28 Pharmaceutical composition containing botulinum neurotoxin
PCT/GB2005/003036 WO2006013357A1 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin a2

Publications (1)

Publication Number Publication Date
ES2526912T3 true ES2526912T3 (es) 2015-01-16

Family

ID=35063257

Family Applications (2)

Application Number Title Priority Date Filing Date
ES14180875.8T Active ES2627627T3 (es) 2004-08-04 2005-08-03 Composición farmacéutica que contiene neurotoxina botulínica A2
ES05767871.6T Active ES2526912T3 (es) 2004-08-04 2005-08-03 Composición farmacéutica que contiene neurotoxina botulínica A2

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES14180875.8T Active ES2627627T3 (es) 2004-08-04 2005-08-03 Composición farmacéutica que contiene neurotoxina botulínica A2

Country Status (9)

Country Link
US (2) US20080069841A1 (es)
EP (3) EP3210620A1 (es)
DK (2) DK1776137T3 (es)
ES (2) ES2627627T3 (es)
HU (1) HUE032950T2 (es)
PL (2) PL2813239T3 (es)
PT (2) PT2813239T (es)
TR (1) TR201708749T4 (es)
WO (1) WO2006013357A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
US8168206B1 (en) * 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
JPWO2010013494A1 (ja) * 2008-07-31 2012-01-05 一般財団法人化学及血清療法研究所 軸索輸送されないボツリヌス神経毒素製剤を含有する医薬組成物およびその利用
US8512715B2 (en) 2008-08-14 2013-08-20 The Cleveland Clinic Foundation Apparatus and method for treating a neuromuscular defect
US9204925B2 (en) 2008-08-14 2015-12-08 The Cleveland Clinic Foundation Apparatus and method for treating a neuromuscular defect
US8506970B2 (en) * 2008-10-14 2013-08-13 Dt Scimed, Llc Dose and localization of botulinum toxins in skin and muscle
EP2379104B1 (en) 2008-12-31 2018-02-28 Revance Therapeutics, Inc. Injectable botulinum toxin formulations
KR20210141783A (ko) 2009-06-25 2021-11-23 레반스 테라퓨틱스, 아이엔씨. 알부민­불포함 보툴리눔 독소 제제
EP2849781B1 (en) * 2012-03-12 2017-09-13 William J. Binder Treatment of migraine headaches with presynaptic neurotoxin
CA2889833A1 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
JP2019526611A (ja) 2016-09-13 2019-09-19 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 非タンパク質クロストリジウム毒素組成物
WO2020231700A1 (en) * 2019-05-11 2020-11-19 Youngsuk Yi Neurotoxin compositions and methods
KR20220169510A (ko) * 2021-06-18 2022-12-28 충북대학교 산학협력단 불멸화 줄기세포의 엑소좀 풍부 배양액 및 보툴리눔 독소를 포함하는 기능성 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2630115B1 (fr) * 1988-04-14 1994-10-28 Merieux Inst Procede de stabilisation des solutions d'albumine humaine et solution obtenue
PT682524E (pt) * 1993-02-02 2002-03-28 Xoma Technology Ltd Composicoes farmaceuticas que contem a proteina bactericida indutora da permeabilidade e um agente tensioactivo
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5756468A (en) 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
CA2521392A1 (en) * 1997-07-15 1999-01-28 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders
US6265379B1 (en) * 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
CN1331532C (zh) 2000-02-08 2007-08-15 阿勒根公司 肉毒杆菌毒素药物组合物
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US6299893B1 (en) * 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US6827931B1 (en) * 2000-10-20 2004-12-07 Allergan, Inc. Method for treating endocrine disorders
WO2003000193A2 (en) * 2001-06-21 2003-01-03 Surromed, Inc. Covalent coupling of botulinum toxin with polyethylene glycol
WO2003082315A1 (fr) * 2002-03-29 2003-10-09 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Remede contre l'hypermyotonie
GB2398636A (en) 2003-02-21 2004-08-25 Ipsen Ltd Method for determining the quantity of pre-synaptic neuromuscular blocking substance contained in a sample
EP1570855A1 (fr) * 2004-03-04 2005-09-07 Claude Le Louarn Utilisation de toxine botulique pour préparer un médicament destiné à prévenir la pousse de poils

Also Published As

Publication number Publication date
WO2006013357A1 (en) 2006-02-09
EP2813239A1 (en) 2014-12-17
DK2813239T3 (en) 2017-06-06
PT2813239T (pt) 2017-06-09
PL1776137T3 (pl) 2015-03-31
TR201708749T4 (tr) 2018-03-21
PT1776137E (pt) 2014-12-31
EP2813239B1 (en) 2017-03-22
US20100184689A1 (en) 2010-07-22
US20080069841A1 (en) 2008-03-20
ES2627627T3 (es) 2017-07-28
EP3210620A1 (en) 2017-08-30
PL2813239T3 (pl) 2017-11-30
EP1776137A1 (en) 2007-04-25
HUE032950T2 (en) 2017-11-28
DK1776137T3 (en) 2015-01-05
EP1776137B1 (en) 2014-11-26

Similar Documents

Publication Publication Date Title
ES2526912T3 (es) Composición farmacéutica que contiene neurotoxina botulínica A2
ES2575152T3 (es) Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
CL2008001951A1 (es) Compuestos derivados de imidazo[1,2-a]pirimidin-2-ilmetil sustituidos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el trastorno del sueno, depresion, ansiedad, trastorno relacionado con el abuso de sustancias, entre otras.
ES2526913T3 (es) Composición farmacéutica que contiene neurotoxina 2 botulínica
ECSP045491A (es) Nueva sal formiato de o-desmetil venlafaxina
UY29437A1 (es) Nuevos antagonistas de cgrp
BRPI0417684A (pt) composto, composição farmacêutica, e, uso de um composto
HN2002000275A (es) Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados
BRPI0417717A (pt) composto, composição farmacêutica, e, uso de um composto
CL2004000467A1 (es) Uso de un anticuerpo contra la subunidad p19 de interleuquina 23 (il-23), para preparar una composicion para el tratamiento de cnacer o de tumores. ]
CL2008001656A1 (es) Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene.
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
GT200600199A (es) Diarilsulfonas sulfonamidas y su uso
NI200600290A (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
AR049915A1 (es) Compuestos con contenido de boro y metodos de uso de los mismos
SV2006002174A (es) Composicion de anticuerpo her2
UY28034A1 (es) Antagonistas de cgrp elegidos, procedimiento para su preparacion asi como su empleo como medicamentos
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
ATE509634T1 (de) Pharmazeutische formulierungen mit incretin- peptid und aprotisch-polarem lösungsmittel
CL2012002844A1 (es) Compuestos derivados de cromen-2-ona; composicion farmaceutica que los comprende; y su uso en el tratamiento de un trastorno proliferativo de celulas tal como cancer (divisional solicitud nº 311-07).
AR066042A1 (es) Moleculas y metodos para modular la proteina convertasa-subtilisina /quexina tipo 9 (pcsk9)
CL2008003527A1 (es) Conjugado de anticuerpo o porcion de union de antigeno del mismo, que se une a la proteina tirosina quinasa 7 (ptk-7/cck4); composicion que lo comprende; acido nulceico cidificante del anticuerpo; vector y celula huesped; uso del conjugado para tratar o prevenir una enfermedad de celulas tumorales que expresan ptk7
BRPI0411316A (pt) uso de uma toxina clostrìdica para reduzir o apetite
CL2007002856A1 (es) Compuestos derivados de pirazolo(1,5)pirimidina; composicion farmaceutica qu lo comprende;y su uso para tratar el cancer.
BRPI0515721A (pt) uso de um inibidor de src cinase e um inibidor de bcr-abl, composição farmacêutica e combinação